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Abstract: Lung cancer is the number one cause of cancer deaths in 
North America and is rapidly increasing worldwide. Although there 
are advances being made in the multidisciplinary management and 
combined-modality therapies of lung cancers, most cases are still 
diagnosed in later noncurable stages. Early detection has hinged on 
clinical risk assessment and on the future possibility of screening by 
low-dose computed tomography of the chest; however, this will only 
vastly increase the number of indeterminate pulmonary lesions (IPLs) 
being detected. Given that the majority of radiographically detected 
lung lesions are benign, and tissue confirmation by various invasive 
biopsy tests has increased risks and costs, a noninvasive adjunctive 
test that can stratify likelihood of an indeterminate lung lesion as 
malignant or benign will be a useful treatment-enabling technology 
to speed up diagnosis and treatment of lung cancers at a more curable 
stage and defer unnecessary invasive procedures that have potential 
for harm. Measurement of transcutaneous bioconductance using the 
differential conductivity properties of cancerous versus benign tissue 
has been previously demonstrated on nonlung lesions. Thus, it has the 
potential of being a noninvasive, simple-to-perform and repeatable 
test that may be valuable in assessing lung lesions. In this prospective 
study of subjects with known thoracic malignancies, computed bio-
conductance measurements discriminated between malignant lesions 
(29 primary lung cancers) from benign pathology (12) across a range 
of IPL sizes (0.8 cm and greater) with a sensitivity of 89.7% (positive 
predictive value 96.3%) and specificity of 91.7% (negative predictive 
value 78.5%). The technology seems to be effective across a range of 
tumor thoracic locations, cell types, and stages. Additional cohorts 
of subjects will be used to validate testing and for refinement of the 
current algorithm, which at present has a test performance with a 
receiver operating characteristic of 90.7%. Noninvasive transcutane-
ous computed bioconductance measurement can become a standard 
risk assessment and therapy-enabling tool in the evaluation of IPLs.
Key Words: American Thoracic Society, Computed bioconductance, 
Computed axial tomography, Noncalcified nodules, Indeterminate 
pulmonary lesion, Receiver operating characteristic.
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Lung cancer is the most frequent cause of cancer deaths worldwide, which are greater in number than those 
caused by colorectal, prostate, and breast cancer combined.1 
In 2011 approximately 226,169 new cases of lung and bron-
chus cancer(totaling about 14% of new cancer diagnoses and 
160,340 deaths or about 28% of all cancer deaths) are expected 
in the United States. 2 There are also more than 1.3 million lung 
cancer deaths annually worldwide.3 Lung cancer is a disease 
for which there are currently no universally accepted screen-
ing methods, hence lung cancer cases are more often diag-
nosed clinically late in their course. Patients have a median 
survival of 6 to 12 months from the time of their diagnosis 
as more than half die within the first year of diagnosis.1,2 The 
longer-term prognosis of patients diagnosed with lung cancer 
in the United States is also poor with a relative 5-year survival 
rate of only 15% with all stages combined.2
Spiral computed tomography (CT) is an important 
advance in imaging technology for a lung cancer workup as 
it is more sensitive than chest radiograph and is able to detect 
small, noncalcified nodules (NCNs).4,5 The recently reported 
outcome from the National Lung Screening Trial in high-risk 
individuals found a 20.3% decrease in mortality, thus provid-
ing encouraging results for the possible value of low-dose 
helical CT in screening “high-risk” populations.6 However, 
there are several impediments to the adoption of screening for 
lung cancer with low-dose CT. These include the risks associ-
ated with radiation exposure even with low-dose CT, and the 
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problem of a large percentage of false-positive findings lead-
ing to invasive workups of lesions that are ultimately found to 
be benign.7–9 Consequently, adjunctive technologies that could 
risk stratify subjects with an indeterminate pulmonary lesion 
(IPL) into a high or a low likelihood of having a true lung can-
cer will be very valuable therapy-enabling tools.
Electrical impedance is by definition the ratio of the voltage 
difference to the current across a circuit or a body (ohm’s law), 
and conductance is the inverse of impedance (1/impedance). The 
dielectrical properties of human cells and tissue are well recog-
nized and are essential for several diagnostic procedures currently 
in use such as the electrocardiograph and electroencephalogram. 
The bioelectrical properties of cancerous tissue have been char-
acterized in scientific and medical literature and shown to vary 
significantly from those of normal, benign tissue.10–24 There is 
no broad consensus regarding the exact mechanism of action of 
this differential property. The mechanism has been attributed to 
the high content of water and sodium within cancerous tissues, 
with the movement of potassium, magnesium, and calcium out 
of the cell.10–14 other possible contributors include not only this 
altered membrane permeability but also changes in membrane 
composition, the nucleus-to-cytoplasm ratio, and alterations in 
cellular composition and density.12,13
Tissue-specific bioconductance has been reported to be 
valuable in the detection of various cancers including skin, 
thyroid, liver, cervix, and breast cancers.14–24 Breast cancer 
has probably been the most extensively studied with biocon-
ductance technology.20–24 Investigators studying patients with 
sonographically or mammographically suspicious lesions have 
found significant differences in electrical conductance between 
normal and abnormal breast tissues..20 By considering electri-
cal conductance results in addition to ultrasound and mam-
mography, the sensitivity of cancer detection increased from 
86 to 95%.21 In contrast, there is limited information regarding 
changes in lung bioconductivity associated with lung cancer 
although a few reports have suggested a relationship.25–27
Based on the above background information regarding 
differences in tissue bioconductance between normal and can-
cerous tissues, a study was performed at another medical cen-
ter under an Institutional Review Board-approved study in 36 
subjects, 18 with diagnosed primary lung cancers, and 18 age- 
and sex-matched controls using the noninvasive transcutane-
ous computed bioconductance (CB) measurement platform 
(Freshmedx, Salt Lake City, UT) . This study found a different 
bioconductance pattern between cancer and control cases.28 This 
provided the basis for further pattern-algorithm development.
The purpose of the current investigation is to examine 
whether transcutaneous CB measurement data can be used 
to further develop an algorithm that discriminates between 




The present research was conducted at a single institu-
tion—Johns Hopkins School of Medicine—and subjects were 
enrolled under an Institutional Review Board-approved pro-
tocol. Potential subjects were informed of the study’s purpose 
and procedures, and signed the informed consent. The study 
subjects were recruited from those considered at risk for lung 
cancer, based on a presentation that included at least one 
suspicious clinical symptom and/or suspicious radiological 
finding. Suspicious clinical symptoms included persistent 
cough, hoarseness, shortness of breath, hemoptysis, fatigue, 
unexplained weight loss, recurrent pneumonia or bronchitis, 
and chest pain. All enrolled subjects had a minimum of one 
recent chest CT (obtained within and up to 14 days before the 
study date) that had demonstrated at least one NCN or lung 
lesion suspicious for lung cancer. other inclusion criteria were 
subjects aged 18 or above, and if women, of nonchildbearing 
potential. Subjects were either to have a biopsy for tissue diag-
nosis within 60 days after the CB measurement or to be fol-
lowed by short-term repeat chest imaging where appropriate.
Exclusion criteria included presence of a pacemaker or 
other implanted electronic devices; patients with known malig-
nancy within the past 5 years except for nonmelanoma skin 
cancer; uncontrolled systemic diseases such as hypertension, 
diabetes, severe heart disease and or/autoimmune disease; use of 
systemic corticosteroid medication; patients having an invasive 
procedure involving the thoracic cavity within 30 days before 
measurement; those having alcohol or drug abuse that may 
interfere with reliable follow-up; an anomalous anatomical or 
physical condition that would preclude accurate cutaneous CB 
measurement; unusually strenuous exercise and other activities 
within 24 hours before measurement that may affect tissue bio-
conductance; patients having radiation or chemotherapy treat-
ment within 30 days before measurement; and those receiving 
current therapy for a documented or suspected chest infection.
As a number of patients presenting with suspicious pulmo-
nary lesions and identified as at-risk for lung cancer will be pres-
ent or former smokers, obstructive airways disease may become 
a confounding factor. To help ascertain whether differential lung 
function may independently affect CB measurements, all study 
subjects will have had recent pulmonary function testing includ-
ing spirometry ordered for clinical purpose. otherwise, enrolled 
subjects performed spirometry as a part of the study according 
to standardized American Thoracic Society criteria.
Fifty-five subjects were enrolled in the study with 41 
evaluable, as described in the Results section. The determina-
tion for subject inclusion or exclusion was made before com-
pleting the final statistical analysis. Patients were recruited 
sequentially and randomly from those who were eligible and 
agreed to participate in the study.
Medical Device
Subjects had a CB test on a single occasion with the trans -
cutaneous Bioconductance Scan Platform (BSP; Freshmedx) 
(Fig. 1). Freshmedx’s CB Test (CB Test), cleared by the 
Johns Hopkins Hospital’s institutional biomedical engineer-
ing staff, delivers a safe current of less than 25 mA to mea-
sure bioconductance between reference electrodes placed on 
the patient’s back or hands and a CB probe placed sequen-
tially at 31 bilateral points on the skin surface. The operator 
views a computer screen that guides placement of the probe 
at these predefined anatomical locations across the thorax 
and other skin sites. The BSP device is designed to reduce 
measurement variability through a probe algorithm that 
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applies specified pressure to the measurement location that is 
independent of technician-applied force. In addition, the device 
software was designed with a quality check embedded in the 
system that checks the measurement and notifies the operator 
whether there is a degradation that could compromise accurate 
measurements. Measurements are obtained 25 times per sec-
ond. Certain locations include diagnostic information whereas 
others provide control, baseline data that allow evaluation 
of technical performance but do not reflect disease state. 
The measurement session requires approximately 20 minutes 
per patient and is completed before any invasive diagnostic 
procedures. The operators (M.Y.Z., S.A.) did not participate 
in other aspects of the subject’s clinical care. The acquired CB 
data were recorded onto a compact disk in a patient-anonymous 
manner, and mailed to a central data center for analysis.
Statistical Analysis
The purpose of this study and statistical analysis was 
to determine whether CB measurements could discriminate 
between malignant pulmonary lesions and benign pathology. In 
the sample size of n = 41 patients, 29 with malignant pulmonary 
lesions and 12 with benign pathology, it would be possible, by 
inspecting and taking advantage of chance patterns in the data, 
to derive an algorithm that combined the data in such a way 
that perfect discrimination could be achieved. optimizing an 
algorithm, then, is intentionally avoided in this study. Instead, 
to establish feasibility, a completely prespecified approach was 
used rather than making decisions after examining the data.
The prespecified data analysis approach was pro-
grammed in Stata version 11 statistical software (StataCorp LP, 
College Station, TX), and validated using previously collected 
pilot data. The current study data were then passed through the 
program, without any interaction or decision by the biostatisti-
cian. This prespecified automated process included all steps 
of the analysis, including the validation step. Even though 
the biostatistician received data in an unblinded fashion, the 
automated data analysis approach provided protection against 
introducing statistician bias, which is similar to the protection 
that full blinding achieves.
The data consisted of CB measurements taken at 31 bilat-
eral anatomical locations. CB measurements consist of various 
bioconductance data such as the maximum or minimum con-
ductance value over a specified time period obtained at each 
anatomical location. These data coupled with the subject’s final 
diagnosis were analyzed using weighted multivariable optimal 
data analysis (oDA).29 The oDA approach selected cutoff 
points for CB measurements that were combined into a com-
posite risk score that maximized discrimination accuracy. The 
composite risk score was calculated through a weighted binary 
approach that coded the best discriminating measurements 
based on their oDA cutoff points as 1 or 0 and then multiplied 
the binary codes by their respected weights that were derived 
in the oDA. That is, the composite risk score = ([1 if the first 
discriminating measurement is  cutoff point, 0 otherwise] 3 
[first weight] + [1 if the second discriminating measurement is 
 cutoff point, 0 otherwise] 3 [second weight] + … + [1 if last 
discriminating measurement is  cutoff point, 0 otherwise] 3 
[last weight])/(sum of weights) 3 100.
This composite score which ranged from 0 to 100 was 
then dichotomized into a binary diagnostic test with a cutoff 
point selected that maximized receiver operating character-
istic (RoC) area. We refer to this as the CB test and report 
its test characteristics: area under the RoC curve, sensitiv-
ity, specificity, positive predictive value (PPV), and negative 
predictive value (NPV). Because the patient sample was a 
random sample, rather than a case-control or cohort sample, 
the estimates of these test characteristics are unbiased and do 
not need special adjustments for verification bias or selection 
bias.30 The RoC area of a binary risk score is simply the aver-
age of sensitivity and specificity.31
With a sample size of 41 patients with measurements 
taken at 31 bilateral locations, the primary threat to the valid-
ity of the statistical analysis was overfitting, which occurs by 
having too many predictor variables for the given sample size, 
so that spurious or unreliable associations are detected in the 
data. Similarly, with many predictor variables, it is possible 
that some can seem to be discriminating simply from chance 
patterns in the data. Likewise, considering all possible cutoff 
points for each variable, again it is possible that chance pat-
terns can arise. These three issues can all result in unreliable 
associations that may not hold up in future patients or data 
sets. The final critical step of the oDA approach, then, is the 
validation step, which corrects for overfitting and unreliable 
associations in the data. To validate the CB test, an internal 
bootstrap validation was performed.32 The bootstrap-validated 
test characteristics are also reported in the next section.
RESULTS
over 15 months, a total of 55 subjects were enrolled in 
the study and evaluated. of these, 41 subjects (22 men and 
19 women) aged 34 to 80 were considered evaluable whereas 
14 were excluded in the final analysis. The reasons for the 14 
exclusions were as follows: 4 subjects who had a diagnosed 
malignancy that was not a primary lung cancer (2 lympho-
mas, 1 pancreatic cancer, and 1 papillary cancer); 3 who were 
lost to follow-up without a definitive final diagnosis; 3 sub-
jects where the lung biopsy was more than 60 days after the 
BSP measurement; 2 subjects who had recent illicit drug use 
(exclusion criteria); 1 subject who had a previous lobectomy 
(may have affected chest anatomy); and 1 who had a lung 
cancer within the previous 5 years. The performance of the 
FIGURE 1. Freshmedx Bioconductance Scan Platform.
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CB test was evaluated in 41 patients with the outcome of 29 
malignant and 12 benign diagnoses.
The 12 patients with benign disease included three 
women and nine men, ranging in age from 34 to 77 years. The 
29 patients with malignancy included 16 women and 13 men, 
ranging in age from 40 to 80 years. The benign group included 
10 white  and 2 black patients whereas the group with malig-
nancies included 18 whites, 10 blacks, and 1 patient of Asian 
descent (Table 1 ).
The 12 benign cases had biopsy results for 9 patients 
that included 6 with benign or inflammatory respiratory 
epithelium, 1 with an epitheloid granuloma, 1 with granu-
lomatous inflammation, and 1 with reactive respiratory epi-
thelium and a fibrous scar. In three cases, the diagnosis of 
benignity resulted from follow-up CT scans that showed a 
decrease in lesion size in one patient at 2 months or a sta-
ble nodule in two patients at 12 months and 24 months on 
follow-up CTs. The lesion sizes in the benign group ranged 
from 0.4 to 3.9 cm with a median size of 2.2 cm. Most of 
the biopsies in the benign cases were performed with bron-
choscopy. However, the patient with the fibrous scar had the 
largest benign lesion (3.9 cm) that was removed by a right 
upper lobectomy (Table 2).
The distribution of cell types from histology and the 
stage results for the 29 malignant cases are shown in Tables 3 
and 4. There was one atypical carcinoid, two small-cell lung 
cancers, and 26 non–small-cell lung cancers. The lesions sizes 
for the 29 malignant cases ranged from 0.8 to 14.6 cm with a 
median size of 3.1 cm.
Spirometry was performed on all patients before the 
CB test; Table 5 shows the distribution within the benign 
and malignant cases. Normal was defined as forced expira-
tory volume in 1 second/forced vital capacity >70%. overall, 
the patients with malignant disease exhibited more airflow 
obstruction with 10 of 28 (1 subject’s results were erroneous) 
or 35.7% having moderate to severely reduced spirometric 
values.
All enrolled patients completed the CB testing with-
out any observed or reported adverse events. The patients 
were also verbally administered a short questionnaire at 
the end of the testing session that asked the following four 
questions: (1) Did the device measurement cause any dis-
comfort and if so, describe; (2) Did the testing time seem 
reasonable? (3) Would you agree to undergo measurement 
again? and (4) Do you have any suggestions for improve-
ment? one patient responded a “little pressure” to the first 
question, and all responded that the testing time was accept-
able. one patient responded “maybe” to undergoing repeat 
measurement and two subjects responded “no.” of the two 
“no” responses, one provided no reason and another cited 
TABLE 1. Patient Demographics
Category All Benign (12) Malignant (29) Excluded (14)
Age (yr)
 Average 64 61 65 66
 Range 34–84 34–77 40–80 48–84
Sex
 Female 26 (47%) 3 (25%) 16 (55%) 7 (50%)
 Male 29 (53%) 9 (75%) 13 (45%) 7 (50%)
Race
 White 38 (69%) 10 (83%) 18 (62%) 10 (71%)
 Black 15 (27%) 2 (17%) 10 (34%) 3 (21%)
 Asian 2 (4%) 0 (0%) 1 (3%) 1 (7%)
 









 T1 (3 cm) 31 (56) 9 (75) 14 (48) 8 (57)
 T2 (>3 cm 7 cm) 19 (35) 2 (17) 11 (38) 6 (43)
 T3 (>7 cm) 4 (7) 0 (0) 4 (14) 0 (0)
Location
 Right upper lobe 20 (36) 5 (42) 10 (34) 5 (36)
 Right middle lobe 5 (9) 1 (8) 3 (10) 1 (7)
 Right lower lobe 10 (18) 1 (8) 6 (21) 3 (21)
 Left upper lobe 9 (16) 1 (8) 5 (17) 3 (21)
 Left lower lobe 11 (20) 4 (33) 5 (17) 2 (14)
Subjects with multiple 
lung lesions
8 (15) 1 (8) 5 (17) 2 (14)
TABLE 3. Histology Distribution in Malignant Group
Histology Malignant (29) (%)
Atypical carcinoid 1 (3)
Minimally invasive or with predominantly  
lepidic features
3 (10)
Squamous cell 6 (21)
Adenocarcinoma 9 (31)
Metastatic adenocarcinoma 8 (27)
Small-cell carcinoma 2 (7)
TABLE 4. Stage Distribution in Malignant Group







TABLE 5. Pulmonary Function Results
Spirometry Results Benign (12) (%) Malignant (29) (%)
Normal 9 (75) 12 (41)
Mildly reduced 2 (17) 6 (21)
Moderately reduced 0 4 (14)
Severely reduced 1 (8) 6 (21)
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excessive travel from home to clinic. No suggestions for 
improvement were made.
Using the weighted multivariable oDA approach for 
analyzing the CB test data resulted in the scatter plot (illus-
trated in Fig. 2) for the 41 patients. As shown here, 11 of the 
12 patients with benign lesions had composite risk scores that 
fell below the cutoff point. For the malignant cases, 26 of the 
29 had composite risk scores above the cutoff point with 3 
falling below it.
Thus, for the 12 benign cases, the CB data resulted 
in 1 false positive and 11 true negatives for a specificity 
of 91.7% and an NPV of 78.5%. After bootstrap valida-
tion, the specificity was 83.3%, 95% confidence inter-
val (CI) (52.8–96.4%) and the NPV was 70.4%, 95% CI 
(41.2–88.9%). In the false-positive case, the patient under-
went a lobectomy with a final diagnosis of a nonnecrotic 
granuloma.
For the 29 malignant cases, there were 26 true posi-
tives and 3 false negatives for a sensitivity of 89.7% and 
a PPV of 96.3%. After bootstrap validation, the sensitiv-
ity was 83.1%, 95% CI (65.5–93.3%) and the PPV was 
92.9%, 95% CI (75.7–98.7%). In the three false-negatives 
cases, one was in the patient with atypical carcinoid can-
cer, whereas histologies from the other two malignant cases 
showed invasive squamous cell cancer with focal basaloid 
features for one and poorly differentiated adenocarcinoma 
for the other.
Further analysis evaluated BSP performance based 
on lesion size, which ranged from 0.4 to 14.6 cm based 
on the CT. The three cases with false-negative results 
had lesion sizes of 2.0, 4.0, and 7.5 cm, whereas the one 
false-positive case had a 2.2-cm mass that was resected by 
lobectomy. Among the cases correctly identified as malig-
nant, there were two subjects with small masses of 0.8 
cm each (Figs. 3 and 4), whereas the largest lesion with 
a benign diagnosis proven by lobectomy was 3.9 cm. The 
RoC area for the continuous composite risk score is illus-
trated in Figure 5, showing an RoC area of 94.5%. After 
dichotomizing the risk score, the binary CB test had an 
RoC of 90.7%. After bootstrap validation, the binary test 
RoC was 83.2%, 95% CI (71.0–95.3%). The lower bound 
of 71.0% of this bootstrap -validated 95% CI is well above 
50%, thus demonstrating a statistically significant result 
(the null hypothesis value for a diagnostic test is RoC of 
50%, where 50% indicates no discriminatory ability of 
the test).
A positive spiral CT showing an IPL was a key enroll-
ment criterion for all subjects; Figures 3 and 4 show the images 
from two malignant cases.
DISCUSSION
The current study of a prospective automated evalua-
tion of patients being assessed for possible lung cancer, using 
the present CB measurement system (Freshmedx BSP), has 
demonstrated distinct patterns of transcutaneous bioconduc-
tance measurements that can distinguish between individuals 
with primary lung cancers and those with a benign process. 
The study was “blinded” in that the CB measurements were 
taken before obtaining knowledge of whether the patient had 
benign or malignant lesions, and effectively blinded for the 
data analysis by using a fully prespecified and preprogrammed 
analysis that did not permit analysis decisions based on the 
data or malignancy status.
The need for noninvasive adjunctive techniques to risk 
stratify indeterminate pulmonary nodules for further evalu-
ation is driven by several well-established facts: that lung 
cancer is the leading cause of cancer mortality in the United 
States and worldwide, and that it most commonly presents as 
radiographic abnormalities of the chest with or without clini-
cal symptoms. Abnormalities in chest imaging, especially seen 
on CT scans of ever-improving resolution, are common find-
ings.4 Such findings, especially as NCNs, are most frequently 
benign in nature. However, with the present poor survival in 
incident lung cancer cases, and the worsened prognosis of 
larger cancers and higher-staged disease, watchful waiting is 
not always an option.33 Although CT-guided needle biopsies, 
video-assisted or open surgical biopsies offer a higher diag-
nostic yield, they are much costlier in financial terms and in 
possible procedure-related morbidities.
FIGURE 2. Patient computerized bioconductance test results.
FIGURE 3. Computed tomography of a patient with a small 
lesion that pathology showed to be a moderately differenti-
ated (G2) squamous cell carcinoma with a stage of T1N0Mx.
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In contrast, there is limited information regarding 
changes in lung bioconductivity associated with lung cancer 
with a few reports noting a relationship.25–27 Kimura et al stud-
ied the extracellular and intracellular resistances and mem-
brane capacitances in three groups of patients: those with lung 
cancers, metastatic cancers to the lung, and organizing pneu-
monias.25 Measurements of the normal lung parenchyma were 
also obtained as each patient acted as his/her own control. This 
study involved an invasive approach of transthoracic insertion 
of a coaxial needle that is used as both the bioconductance 
measurement and tissue biopsy device. Although interesting 
observations can be made that a lung mass or consolidation 
(organizing pneumonia) has lower extracellular resistance than 
normal lung parenchyma, with a pneumonia having the low-
est number, there were only 4 organizing pneumonias versus 
49 cancers (44 lung primaries and 5 metastases); hence it is 
difficult to draw firm conclusions about difference in tissue 
conductance between these two groups. The authors concluded 
that a coaxial biopsy needle outfitted for bioconductance mea-
surement may be useful in guiding biopsy, of when abnormal 
lung tissue is reached,  hence it is really an adjunctive device 
for biopsy rather than for preinvasive assessment.
In a single, prior noninvasive study of bioconductance 
measurement in lung cancer subjects, the focus was on com-
paring bioelectric impedance vector analysis in patients with 
known advanced-stage (IIIB and IV) lung cancer (66) versus 
healthy controls (56).26 The conclusion drawn in the study by 
Toso et al is that a distinct difference in transcutaneous bio-
impedance (a combination of resistance and capacitance) can 
be seen between patients with advanced lung cancer and nor-
mal controls, and that in the advanced cancer cohort, regard-
less of their measured body mass index, one commonly used 
the index of nutrition, bioconductance measurement differ-
ences provided a better measurement of survival, and hence 
prognosis. No mention was made of how their technology or 
methodological approach may be used in the pretissue diag-
nostic realm. Finally, a third study used electrical impedance 
tomography to provide in vivo imaging before surgery in 22 
patients with single-sided lung cancer and 7 healthy subjects.27 
These investigators found that images in 19 of the 22 affected 
lung cancer patients showed differences in conductivity that 
were statistically different from the average conductivity of a 
healthy lung.
FIGURE 4. Panels A, B and C show computed tomography images of a patient with a small 
moderately differentiated (G2) adenocarcinoma with bronchoalveolar features. This patient was 
staged as T1N0M0.
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An earlier study of CB in 36 subjects (18 lung cancer 
proven and 18 age- and sex-matched control cohort) provided 
encouraging preliminary data, though using different equip-
ment and measurement parameters by demonstrating a distinct 
pattern of bioconductance with a transcutaneous approach.28 
In the present study, using a prespecified risk score algorithm 
noted to be useful in distinguishing patients with cancer ver-
sus normal controls in the earlier study, the algorithm was 
applied to the current data to generate a continuous composite 
risk score. The “optimal” cutoff point for the composite score 
(Fig. 2) that produced a binary test correctly identifies 26 of 
29 lung cancer cases as true positives (sensitivity 89.7%), 
and only 1 false positive (PPV 96.3%); the same cutoff point 
identified 11 of 12 benign lesions as true negatives (specific-
ity 91.7%), but as there were 3 false negatives with this cutoff 
point, the NPV is 78.5%. The area under the curve of the RoC 
(Fig. 5) using the attributes chosen is a robust 94.5%, which 
remained high at 90.7% after converting to a binary test. It is 
possible to shift the cutoff point to further favor an increased 
sensitivity and higher NPV, but this will decrease the specific-
ity. If used as a risk-stratifying test before tissue diagnosis, 
this will increase biopsies of benign lesions. It is recognized 
that the two cases considered in the benign categorization 
were based on follow-up CT results rather than biopsy, so their 
diagnosis is not completely definitive although consistent with 
current clinical practice.
of the 29 proven lung cancers, 14 (48%) were T1 can-
cers, 11 (38%) were T2 and 4 (14%) were T3 (Table 2). The 3 
false-negative cases (10.3%) were 2, 4.7, and 7.5 cm, whereas 
two 0.8 cm non–small-cell lung cancers were correctly identi-
fied by the combination score cutoff (Fig. 2), hence the size 
of primary cancer did not seem to affect usefulness of the CB 
composite risk score. Adenocarcinoma formed the majority 
(58%) cell type in the primary lung cancer cohort, perhaps 
not surprising because the subjects were selected on the basis 
of a visible peripheral lung mass. of note, the three cases of 
adenocarcinoma classified as bronchioloalveolar cell were all 
accurately classified as cancer (Fig. 4).
The prior study by Kimura et al25 of needle puncture 
into tissue observed the extracellular resistance and mem-
brane capacitance differences between lung parenchyma and 
a lung mass, but no distinction was made between normal ver-
sus emphysematous versus fibrotic lung parenchyma. Because 
the majority of lung cancer patients continue to be active or 
ex-smokers who may have coexisting obstructive lung disease 
of varying severity, we collected spirometric measurements on 
all the patients (Table 5). There is no pattern of combination 
bioconductance measurements to suggest that the degree of 
airflow obstruction significantly affects the CB combination 
score that may mistakenly identify an epiphenomenon (air-
flow obstruction).
There are other noninvasive tests that have been used 
to further characterize an IPL to improve the discrimination 
of whether such a lesion is malignant or benign, but these 
are most commonly additional radiology studies that expose 
patients to higher and cumulative dosages of ionizing radia-
tion. The use of timed contrast injection to measure nodule 
enhancement is useful for solid nodules and, with a minimum 
cutoff point of 15 Hounsfield unit (HU), has a high sensitivity 
(98%) and a high NPV in a study with 356 suspicious nodules. 
With this 15-HU threshold, the specificity is only 58%, and 
little is known about its utility for nonsolid lesions.34 Instead, 
18-fluorodeoxyglucose (FDG) positron emission tomography 
(PET) metabolic scanning is ever more likely to be used as a 
follow-up imaging adjunct in the evaluation of the suspicious 
solitary pulmonary nodule, with sensitivities of 92 to 96% and 
specificities of 77 to 90%.35,36
There has been a prospective study of 42 nodules evalu-
ated by both techniques, with the conclusion that 18-FDG PET 
scans offer a higher specificity of 90% and above with mini-
mal loss of sensitivity .37 The authors, all experts in this field, 
acknowledge the trade-off because contrast-enhanced CT is 
more easily available and cheaper to perform. Conversely, 
PET scans are costly, not widely available outside of North 
America, Western Europe, and the more developed larger cit-
ies on other continents. Furthermore, whereas 18-FDG-PET 
has an overall sensitivity of more than 90% in identifying the 
malignant pulmonary nodule, its diagnostic sensitivity falls in 
smaller (<1.0 cm) lesions and again in the nonsolid adeno-
carcinoma that are minimally invasive or presenting with a 
lepidic alveolar cell features. These smaller lesions and non-
solid lesions are also the ones that pose a bigger challenge 
in diagnosing with minimally invasive transthoracic needle or 
bronchoscopic techniques.
In our present study, all patients have high-resolution 
CT scans, most often with intravenous contrast, but we do not 
have a protocol for dynamic contrast enhancement with timed 
measurement of changes in the HU measurement of the nod-
ule. This would entail multiple scans with attendant increase 
in exposure to ionizing radiation. A number of our subjects did 
have a 18-FDG-PET scan that had been ordered for the evalu-
ation of the nodules. However, even though 36 of 55 subjects 
did have PET scans, these were performed at various facilities 
FIGURE 5. Receiver operating characteristic performance of 
the computed bioconductance test.
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with no standard methodology of reading or scoring uptake 
value, therefore we did not perform further subgroup analysis. 
This comparison can be of great interest if prospectively stud-
ied with standardized reading for the 18-FDG uptake.
We have not studied our patients with the BSP lon-
gitudinally with multiple CB in-series, as all patients were 
scheduled to have some form of tissue diagnosis on follow-up 
within 60 days,  at which time the individual patient’s study 
was considered complete. There were no device-related or 
study-associated adverse events, and only 2 of 55 subjects 
indicated “no” to repeat testing, citing inconvenience as the 
reason. It will be of interest to repeat measurement in all 
groups of patients, those with benign tissue diagnosis, and 
those who were followed to resolution of their suspicious pul-
monary lesions; it is unknown whether the CB profile will 
remain static or change with radiographic findings. A sepa-
rate pattern of change could be expected in patients with lung 
cancers who then underwent curative surgery, and of further 
interest and intrigue is whether a “cancer” profile should recur 
with cancer recurrence and/or development of a second pri-
mary lung cancer after surgical cure of the primary cancer. 
In the group of patients with nonsurgical lung cancer who are 
treated with standard combination of chemotherapy with and 
without radiation, it will be interesting to see whether serial 
measurements change as the disease responds or progresses, 
as is suggested in the Toso study.26 The current cutoff point 
provides a binary response of risk assessment. Serial mea-
surements of the same patient or larger study cohorts may 
provide a rationale to subdivide the combination score into 
subgroups of negative, low index, medium index, and high 
index of suspicion for lung cancer. A slope of serial combi-
nation score may be compared to currently accepted modes 
of serial assessment, Response Evaluation Criteria in Solid 
Tumors criteria, 18-FDG standard uptake values (SUV), and 
Eastern Cooperative oncology Group functional status to 
determine whether it may provide prognostic information.
As discussed in the Statistical Analysis section, the 
CB test was a prespecified statistical analysis plan, with no 
effort made to maximize its performance. Review of patient-
related factors such as age, sex, race, and body mass index 
as possible contributors to a subject’s composite score did 
not show a clear correlation when examined in this relatively 
small patient population but may prove to be of value when 
larger patient groups are investigated. The sample size, par-
ticularly only having 12 benign cases, is a limitation of this 
study. Further clinical investigations are ongoing and refine-
ment of the algorithm that discriminates between malignant 
and benign lesions continues to be in progress.
CONCLUSIONS
In this article, we are for the first time describing the 
use of transcutaneous CB measurements, which is noninva-
sive and does not expose the patient to ionizing radiation, that 
may offer a highly distinguishing signal between malignant 
and benign lesions. This test may be applied as a first-step 
risk-stratification adjunctive procedure in the evaluation of 
the IPL. Additional studies may include prospectively apply-
ing the presently developed algorithm of the CB test based 
on the present training set to new tests or validation sets of 
cohorts of patients with IPLs. There will be opportunity to 
further refine the present algorithm by inclusion of more 
patients with varying lung pathologies, malignant and benign. 
There will also be continued development by elimination of 
low-performance anatomic location measurement points, and 
by the testing of new measurement points that may further 
enhance the overall performance characteristic of CB mea-
surement. Qualities such as ease of testing and repeatability 
open up potential future applications of this technology in 
specific high-risk populations for the early detection of dis-
ease recurrence after initial treatment response, emergence of 
second primary lung cancers, and as a potential technology 
for lung cancer screening.
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